wLLY
WeildXTokenized equityEli Lilly and Company
wLLY is mapped to Eli Lilly and Company for informational coverage. Eli Lilly and Company is not represented as the token issuer.
wLLY
XRPL token market
wLLY news intelligence
Verified source composition and publication cadence mapped to the exact wLLY XRPL identity.
- Coverage records
- 13
- Source channels
- 3
- Official sources
- 13
- Dated events
- 11
wLLY source and story topology
Trace every mapped record from its source role to this exact XRPL identity and the other registered markets it genuinely shares.
- Native records
- 13 Mapped to wLLY
- Source channels
- 3 Named publishers
- Official records
- 13 Explicitly labeled
- Connected markets
- 38 Shared source records
rwhCoTx1...k99PnDvEXACT IDENTITY11 dated records are available for chronological analysis.
Connections represent shared source records, not price correlation, endorsement, ownership, or issuer quality. Every market node resolves through the exact registered currency and issuer.
More tokenized equities
Continue through exact XRPL identities with verified issuer and reference-source separation.
wLLY coverage
13 sourcesFDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Official Eli Lilly and Company company announcement. Read the original release for details. This concerns the underlying company, not the issuer of wLLY.
Eli Lilly and Company official disclosures and company updates
Official Eli Lilly and Company information mapped to wLLY through its reviewed LLY underlying reference. The company is not represented as the token issuer.
WeildX issuer information and asset notices
Issuer-specific information for supported WeildX assets. Kept separate from news about each underlying company.
